EDSA vs. VTGN, ANL, ZIVO, GNTA, SNTI, CUE, PMVP, CNTB, MGX, and IFRX
Should you be buying Edesa Biotech stock or one of its competitors? The main competitors of Edesa Biotech include VistaGen Therapeutics (VTGN), Adlai Nortye (ANL), ZIVO Bioscience (ZIVO), Genenta Science (GNTA), Senti Biosciences (SNTI), Cue Biopharma (CUE), PMV Pharmaceuticals (PMVP), Connect Biopharma (CNTB), Metagenomi (MGX), and InflaRx (IFRX). These companies are all part of the "pharmaceutical products" industry.
Edesa Biotech vs. Its Competitors
VistaGen Therapeutics (NASDAQ:VTGN) and Edesa Biotech (NASDAQ:EDSA) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, valuation, earnings, profitability and media sentiment.
VistaGen Therapeutics has a beta of 0.61, meaning that its stock price is 39% less volatile than the S&P 500. Comparatively, Edesa Biotech has a beta of 0.39, meaning that its stock price is 61% less volatile than the S&P 500.
In the previous week, VistaGen Therapeutics and VistaGen Therapeutics both had 1 articles in the media. Edesa Biotech's average media sentiment score of 1.00 beat VistaGen Therapeutics' score of 0.00 indicating that Edesa Biotech is being referred to more favorably in the news media.
78.4% of VistaGen Therapeutics shares are owned by institutional investors. Comparatively, 5.5% of Edesa Biotech shares are owned by institutional investors. 1.3% of VistaGen Therapeutics shares are owned by insiders. Comparatively, 22.6% of Edesa Biotech shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Edesa Biotech has a net margin of 0.00% compared to VistaGen Therapeutics' net margin of -6,777.08%. VistaGen Therapeutics' return on equity of -58.88% beat Edesa Biotech's return on equity.
Edesa Biotech has lower revenue, but higher earnings than VistaGen Therapeutics. Edesa Biotech is trading at a lower price-to-earnings ratio than VistaGen Therapeutics, indicating that it is currently the more affordable of the two stocks.
Edesa Biotech has a consensus target price of $5.00, suggesting a potential upside of 134.74%. Given Edesa Biotech's stronger consensus rating and higher probable upside, analysts clearly believe Edesa Biotech is more favorable than VistaGen Therapeutics.
Summary
Edesa Biotech beats VistaGen Therapeutics on 8 of the 15 factors compared between the two stocks.
Get Edesa Biotech News Delivered to You Automatically
Sign up to receive the latest news and ratings for EDSA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding EDSA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Edesa Biotech Competitors List
Related Companies and Tools
This page (NASDAQ:EDSA) was last updated on 7/5/2025 by MarketBeat.com Staff
